Conference Coverage

Remote Assessments: A Win-Win for ALS Patients and Clinics?


 

FROM AANEM 2024

Best of Both Worlds

Ileana Howard, MD, physiatrist and professor of rehabilitation medicine at the University of Washington and medical co-director of the ALS Center of Excellence at VA Puget Sound in Seattle, agreed.

“One of the biggest challenges in ALS care today is ensuring equitable access to high quality care and supports, and telehealth was adopted by the VA early on as a means of doing that,” she said. “Remote monitoring technology is a really key development to help improve that type of care.”

However, she added that it should not be a question of one type of care versus the other. “The ideal care is when we have access to providing both face-to-face and virtual care for our patients so that we can meet their needs and preferences for care,” she said.

“Sometimes, in my experience, patients don’t understand why it’s important to go to an ALS specialty center. In those cases, I’ve been able to make initial contact with those individuals through telehealth and be able to provide education, which, in turn, often results in them making the decision to come to the specialty center once they understand what resources we have to offer.”

Also commenting on the research, Ghazala Hayat, MD, also endorsed a mixed approach.

“Telehealth is a very good tool that we should use interspersed with in-person visits,” said Hayat, director of the multidisciplinary ALS clinic at St. Louis University School of Medicine, St. Louis, Missouri, and professor of neurology and director of neuromuscular and clinical neurophysiology.

“I think the first few visits should always be in person — you need to connect with the patient,” she said. “But then, once they feel comfortable, remote monitoring is a very good idea, especially later in the disease process, when it becomes really difficult for the family to bring the patient in.”

The authors reported no relevant disclosures. Howard reported no disclosures. Hayat reported serving as a speaker and in advisory roles for argenx, Alexion, and MTPA. The study was funded by Amylyx Pharmaceuticals.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Untangling CIDP
MDedge Neurology
Myasthenia Gravis: Patient Choice, Cultural Change
MDedge Neurology
First-in-Class B-Cell Depleting Agent Promising for Myasthenia Gravis
MDedge Neurology
Sustained Control with Investigational Monoclonal Antibody for Myasthenia Gravis
MDedge Neurology
At Last, Treatment Is in Sight for Charcot-Marie-Tooth Disease
MDedge Neurology
Myasthenia Gravis: Similar Symptoms in Relatives Raise Question of Genes
MDedge Neurology
ALS Update: Drug Therapy Continues to Offer Little Benefit
MDedge Neurology
Cardiac Monitoring Is Crucial in Neuromuscular Disorder Care
MDedge Neurology
New Clinician Tool Aims to Stop ALS Diagnosis Delays
MDedge Neurology
Pediatric Myasthenia Gravis: Don’t Treat Children Like Adults
MDedge Neurology